Neoadjuvant 177Lu-DOTATATE for non-functioning pancreatic neuroendocrine tumours (NEOLUPANET): multicentre phase II study.

Stefano PartelliLuca LandoniMirco BartolomeiAlessandro ZerbiChiara Maria GranaUgo BoggiGiovanni ButturiniRiccardo CasadeiRoberto SalviaMassimo Falconi

Published in: The British journal of surgery (2024)

Neoadjuvant treatment with 177Lu-DOTATATE is safe and effective for patients with NF-PanNETs.

Keyphrases

locally advanced
phase ii study
rectal cancer
pet ct
squamous cell carcinoma
lymph node
neuroendocrine tumors
radiation therapy
signaling pathway
clinical trial
oxidative stress
study protocol
immune response
cell proliferation